Given unmet medical need, differentiated product profile, and competitor having large recall last year, I believe the commercial opportunity for Ascendis Pharma's TransCon treatment for PTH patients is not fully priced into the stock. I believe there is significant re-rating potential for Ascendis as well as M&A optionality.